Company news
Celldex Therapeutics, Inc. news in 2025
Celldex Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
December 8, 2025
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 9, 2025
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
November 9, 2025
Celldex to Present at Upcoming Investor Conferences
November 6, 2025
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20
November 6, 2025
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patient...
November 5, 2025
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
November 5, 2025
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
October 29, 2025
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
September 16, 2025
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
September 8, 2025
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
August 18, 2025
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 6, 2025
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
June 13, 2025
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
June 11, 2025
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
June 9, 2025
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
June 5, 2025
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 7, 2025
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
May 4, 2025
Celldex Therapeutics to Present at Upcoming Investor Conferences
March 3, 2025
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
March 2, 2025
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
February 28, 2025
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
February 26, 2025
Calls in 2025
Decks in 2025
- EAACI Congress 2025
Conference · 14 slides · Jun 13, 2025